Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × tetrathiomolybdate × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Neoplasm, Residual 1

Interventions

palbociclib 2 Trastuzumab 2 Capecitabine 2 trastuzumab deruxtecan 1 tetrathiomolybdate 1 sacituzumab govitecan 1 pembrolizumab 1 niraparib 1 inavolisib 1 giredestrant 1 eribulin 1 avelumab 1 atezolizumab 1 abemaciclib 1 Zymosan 1 Radiotherapy 1 Letrozole 1 Immunotherapy 1 Hydroxychloroquine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡